Nextage Therapeutics (XTAE:NXTG) Debt-to-Asset : 0.35 (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Nextage Therapeutics Debt-to-Asset?

Nextage Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.31 Mil. Nextage Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪0.07 Mil. Nextage Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was ₪1.10 Mil. Nextage Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.35.

Nextage Therapeutics Debt-to-Asset Historical Data

The historical data trend for Nextage Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextage Therapeutics Debt-to-Asset Chart

Nextage Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

3.52

0.21

0.32

0.22

0.35

Nextage Therapeutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial									0.32	0.12	0.22	0.86	0.35

Competitive Comparison of Nextage Therapeutics's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextage Therapeutics's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Nextage Therapeutics's Debt-to-Asset falls into.

Nextage Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Nextage Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.308	+	0.07)	/	1.095
	=	0.35

Nextage Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.308	+	0.07)	/	1.095
	=	0.35

Nextage Therapeutics (XTAE:NXTG) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Nextage Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Nextage Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextage Therapeutics (XTAE:NXTG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nextage Therapeutics Ltd (XTAE:NXTG) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bio-Light, Kiryat Atidim 7, Entrance 1, 2rd Floor, Tel Aviv, ISR, 61581

Website

http://www.m-medic.com

Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.

Nextage Therapeutics (XTAE:NXTG) Headlines

From GuruFocus

First Trust Global Portfolios Limited Announces Name Changes for Certain Sub-Funds of First Trust Global Funds plc

By Business Wire Business Wire • 01-29-2021